Bioengineered wharton's jelly derived extracellular matrix

Patent metadata

Field	Value
Publication number	US-12472282-B2
Application number	US-201917043927-A
Country	US
Kind code	B2
Filing date	Mar 29, 2019
Priority date	Mar 30, 2018
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

The present invention provides bioengineered extracellular matrix model derived from decellularized Wharton's jelly matrix (DWJM) and methods for making and using the same. After decellularization, the DWJM is homogenized, frozen, and lyophilized in a mold to form a molded scaffold having a substantially uniform pore size, pore distribution, and matrix component distribution, and can be trimmed and shaped to any desired size. The bioengineered DWJM is able to maintain the stem cell qualities of cultured cells, which is useful in screening chemotherapy drugs that target cancers, especially cancer stem cell populations. The bioengineered DWJM possesses matrix components similar to the bone hematopoietic niche and is useful in expanding and maintaining hematopoietic stem cells as well as promoting bone regeneration and repair.

First claim

What is claimed is:

1 . A porous matrix comprising molded homogenized decellularized Wharton's jelly matrix (DWJM) having:
a median pore size between about 200 μm and about 350 μm, and a pore size distribution that is no more than 50% or 17% of the median pore size.

2 . The porous matrix of claim 1 , wherein the median pore size is between about 230 μm and about 330 μm.

3 . The porous matrix of claim 1 , wherein the median pore size is about 235 μm, about 275 μm, about 290 μm, about 300 μm, about 310 μm, about 320 μm, or about 330 μm.

4 . The porous matrix of claim 1 , having a volumetric porosity of between about 80% and 95%.

5 . The porous matrix of claim 1 , further comprising a homogenous distribution of a matrix component selected from the group consisting of: collagen, fibronectin, tenascin C (TN-C), fibrillin, lumican, hyaluronic acid (HA), versican, fibrinogen gamma chain, myosin-9, myosin-10, paladin, filamin, vinculin, moesin, periostin, laminin, talin-1, and combinations thereof.

6 . The porous matrix of claim 1 , having a fibrinogen gamma chain abundance ratio of between about 30 and 35.

7 . The porous matrix of claim 1 , having a myosin-9 abundance ratio of between about 10 and 15.

8 . The porous matrix of claim 1 , having a myosin-10 abundance ratio of between about 10 and 15.

9 . The porous matrix of claim 1 , wherein the matrix is molded or trimmed to a disc shape sized to fit in a cell culture well.

10 . The porous matrix of claim 1 , further comprising at least one population of seeded cells.

11 . The porous matrix of claim 1 , further comprising at least one therapeutic agent.

12 . A method of culturing hematopoietic stem cells, comprising the steps of seeding CD34+ cells onto the porous matrix of claim 1 , wherein the cells maintain quiescence while cultured on the porous matrix.

13 . The method of claim 12 , wherein the seeded CD34+ cells have megakaryocyte lineage bias.

Assignees

• Univ Rochester

Inventors

• Aljitawi Omar
• Awad Hani
• Becker Michael

Classifications

• G01N33/5011

  for testing antineoplastic activity · CPC title

• C12N2533/90

  Substrates of biological origin, e.g. extracellular matrix, decellularised tissue · CPC title

• C12N2503/02

  Drug screening · CPC title

• C12N5/0647

  Haematopoietic stem cells; Uncommitted or multipotent progenitors · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title